logo
logo
COR stock ticker logo

Cencora, Inc.

NYSE•COR
執行長: Mr. Steven H. Collis
板塊: Healthcare
行業: Medical - Distribution
上市日期: 1995-04-04
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
聯絡資訊
1 West First Avenue, Conshohocken, PA, 19428-1800, United States
610-727-7000
www.cencora.com
市值
$69.89B
本益比 (TTM)
42.9
33.7
股息率
0.6%
52周最高
$377.54
52周最低
$248.59
52周範圍
86%
排名13Top 2.2%
6.8
F-Score
改良版 Piotroski 分析
基於 10 年期基本面
強勁 • 6.8 / 9 分
評分區間 (0-9)
8-9: 價值優異
6-7: 基本面強勁
4-5: 整體穩健
0-3: 表現疲弱
資料區間: 2016-2025

財務儀表板

Q1 2026 數據

營業收入

$85.93B+0.00%
近4季度走勢

每股收益

$2.88+0.00%
近4季度走勢

自由現金流

-$2.42B+0.00%
近4季度走勢

2026 Q1 財報亮點

核心亮點

Revenue Growth Strong Revenue reached $85.93 B USD for the quarter, marking a solid 5.5% increase over the prior year period.
Gross Profit Surges Gross profit surged to $3.07 B USD, showing a strong 20.1% increase driven by recent acquisitions.
Net Income Improvement Net income attributable to Cencora grew to $559.65 M USD, improving significantly from $488.60 M USD last year.
Operating Cash Usage Down Cash used in operating activities decreased by $0.4 B USD, totaling $2.31 B USD utilized this quarter.

關注風險

Opioid Litigation Liability Accrued litigation liability for opioid settlements stands at $4.3 B USD, payable across the next thirteen years.
Asset Impairment Recorded Management recorded a $165.7 M USD goodwill impairment charge related to the U.S. Consulting Services business sale.
Interest Expense Spikes Net interest expense increased substantially by 159.2% due to significant new debt issuance for acquisitions.
Geopolitical Uncertainties Remain Exposure remains high regarding geopolitical uncertainties, macroeconomic shifts, and potential supply chain disruptions globally.

未來展望

OneOncology Acquisition Closed The company finalized the majority acquisition of OneOncology for approximately $4.6 B USD cash in February 2026.
New Segment Reporting A new business reporting structure aligning with growth priorities was implemented starting in the first quarter of fiscal 2026.
Credit Facility Expanded The Multi-Currency Revolving Credit Facility was amended, increasing total commitments available up to $5.5 B USD.
Quarterly Dividend Raised Anticipating continued capital needs, the Board increased the quarterly common stock dividend by 9% to $0.60 USD.

同行對比

營業收入 (TTM)

MCK stock ticker logoMCK
$397.96B
+15.5%
COR stock ticker logoCOR
$325.78B
+7.4%
CAH stock ticker logoCAH
$244.49B
+10.1%

毛利率 (最新季度)

ARGX stock ticker logoARGX
89.3%
-53.8pp
REGN stock ticker logoREGN
85.0%
+3.3pp
EW stock ticker logoEW
78.3%
-2.7pp

關鍵指標

股票代碼
市值
本益比 (TTM)
股東權益報酬率 (TTM)
負債率
MCK$114.95B26.4-245.3%10.2%
REGN$79.48B17.514.8%6.7%
COR$69.89B42.9101.4%10.1%

長期趨勢

近4季度
營業收入
淨利
營運現金流
4季度營業收入複合增長率
4.4%
溫和增長
4季度淨利複合增長率
-8.0%
盈利能力下滑
現金流穩定性
75%
現金流波動較大

深度研究

下次財報:2026年5月5日
|
每股收益:-
|
營業收入:-
財務數據
電話會議
財務報告
新聞
損益表
資產負債表
現金流量表
財務比率
變化率
損益表
過去12個月
無資料